These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33407171)

  • 21. Associations of Fecal Short Chain Fatty Acids With Colonic Transit, Fecal Bile Acid, and Food Intake in Irritable Bowel Syndrome.
    Waseem MR; Shin A; Siwiec R; James-Stevenson T; Bohm M; Rogers N; Wo J; Waseem L; Gupta A; Jarrett M; Kadariya J; Xu H
    Clin Transl Gastroenterol; 2023 Jan; 14(1):e00541. PubMed ID: 36227781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated fecal microbiome-metabolome signatures reflect stress and serotonin metabolism in irritable bowel syndrome.
    Mujagic Z; Kasapi M; Jonkers DM; Garcia-Perez I; Vork L; Weerts ZZRM; Serrano-Contreras JI; Zhernakova A; Kurilshikov A; Scotcher J; Holmes E; Wijmenga C; Keszthelyi D; Nicholson JK; Posma JM; Masclee AA
    Gut Microbes; 2022; 14(1):2063016. PubMed ID: 35446234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fecal short-chain fatty acids in non-constipated irritable bowel syndrome: a potential clinically relevant stratification factor based on catabotyping analysis.
    Gargari G; Mantegazza G; Taverniti V; Gardana C; Valenza A; Rossignoli F; Barbaro MR; Marasco G; Cremon C; Barbara G; Guglielmetti S
    Gut Microbes; 2023 Dec; 15(2):2274128. PubMed ID: 37910479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations in fecal short chain fatty acids (SCFAs) and branched short-chain fatty acids (BCFAs) in men with benign prostatic hyperplasia (BPH) and metabolic syndrome (MetS).
    Ratajczak W; Mizerski A; Rył A; Słojewski M; Sipak O; Piasecka M; Laszczyńska M
    Aging (Albany NY); 2021 Apr; 13(8):10934-10954. PubMed ID: 33847600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alterations in serotonin metabolism in the irritable bowel syndrome.
    Thijssen AY; Mujagic Z; Jonkers DM; Ludidi S; Keszthelyi D; Hesselink MA; Clemens CH; Conchillo JM; Kruimel JW; Masclee AA
    Aliment Pharmacol Ther; 2016 Jan; 43(2):272-82. PubMed ID: 26538292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential Roles of Enterochromaffin Cells in Early Life Stress-Induced Irritable Bowel Syndrome.
    Tao E; Zhu Z; Hu C; Long G; Chen B; Guo R; Fang M; Jiang M
    Front Cell Neurosci; 2022; 16():837166. PubMed ID: 35370559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex-based differences in fecal short-chain fatty acid and gut microbiota in irritable bowel syndrome patients.
    Sun QH; Liu ZJ; Zhang L; Wei H; Song LJ; Zhu SW; He MB; Duan LP
    J Dig Dis; 2021 May; 22(5):246-255. PubMed ID: 33822477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome.
    Zou BC; Dong L; Wang Y; Wang SH; Cao MB
    Chin Med J (Engl); 2007 Dec; 120(23):2069-74. PubMed ID: 18167178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis.
    Liu HN; Wu H; Chen YZ; Chen YJ; Shen XZ; Liu TT
    Dig Liver Dis; 2017 Apr; 49(4):331-337. PubMed ID: 28179092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome?
    Farup PG; Rudi K; Hestad K
    BMC Gastroenterol; 2016 Apr; 16(1):51. PubMed ID: 27121286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement.
    Jacobs JP; Gupta A; Bhatt RR; Brawer J; Gao K; Tillisch K; Lagishetty V; Firth R; Gudleski GD; Ellingson BM; Labus JS; Naliboff BD; Lackner JM; Mayer EA
    Microbiome; 2021 Nov; 9(1):236. PubMed ID: 34847963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bifico relieves irritable bowel syndrome by regulating gut microbiota dysbiosis and inflammatory cytokines.
    Zhou Y; Zhang F; Mao L; Feng T; Wang K; Xu M; Lv B; Wang X
    Eur J Nutr; 2023 Feb; 62(1):139-155. PubMed ID: 35918555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fecal Fermentation in Irritable Bowel Syndrome: Influence of Dietary Restriction of Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols.
    Valeur J; Røseth AG; Knudsen T; Malmstrøm GH; Fiennes JT; Midtvedt T; Berstad A
    Digestion; 2016; 94(1):50-6. PubMed ID: 27487397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fecal Microbiota Signatures Are Not Consistently Related to Symptom Severity in Irritable Bowel Syndrome.
    Wang T; Rijnaarts I; Hermes GDA; de Roos NM; Witteman BJM; de Wit NJW; Govers C; Smidt H; Zoetendal EG
    Dig Dis Sci; 2022 Nov; 67(11):5137-5148. PubMed ID: 35624331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome.
    Cremon C; Carini G; Wang B; Vasina V; Cogliandro RF; De Giorgio R; Stanghellini V; Grundy D; Tonini M; De Ponti F; Corinaldesi R; Barbara G
    Am J Gastroenterol; 2011 Jul; 106(7):1290-8. PubMed ID: 21427712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome.
    Mishima Y; Ishihara S
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of five diarrhea-predominant irritable bowel syndrome (IBS-D) rat models in the brain-gut-microbiota axis.
    Wu H; Zhan K; Rao K; Zheng H; Qin S; Tang X; Huang S
    Biomed Pharmacother; 2022 May; 149():112811. PubMed ID: 35303570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine regulation of gut function - a role for glucagon-like peptide-1 in the pathophysiology of irritable bowel syndrome.
    O'Malley D
    Exp Physiol; 2019 Jan; 104(1):3-10. PubMed ID: 30444291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of brain networks and fecal metabolites reveals brain-gut alterations in premenopausal females with irritable bowel syndrome.
    Osadchiy V; Mayer EA; Gao K; Labus JS; Naliboff B; Tillisch K; Chang L; Jacobs JP; Hsiao EY; Gupta A
    Transl Psychiatry; 2020 Nov; 10(1):367. PubMed ID: 33139708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.